Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Journal of Immunology (Baltimore, Md. : 1950)|November 23, 2005
Human CD4+ T cells induced by synthetic peptide malaria vaccine are comparable to cells elicited by attenuated Plasmodium falciparum sporozoitesJaime Mauricio Calvo-Calle, Giane A Oliveira, Elizabeth H NardinJournal of Immunological Methods|September 8, 2004
Quantitative Plasmodium sporozoite neutralization assay (TSNA)Kota Arun Kumar, Giane A Oliveira, Robert Edelman, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 10, 2002
Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite proteinCathrine Persson, Giane A Oliveira, Ali A Sultan, et al.Infection and Immunity|October 13, 2006
A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challengeJ Mauricio Calvo-Calle, Giane A Oliveira, Carol Othoro Watta, et al.Infection and Immunity|December 28, 2007
Class II-restricted protective immunity induced by malaria sporozoitesGiane A Oliveira, Kota Arun Kumar, J Mauricio Calvo-Calle, et al.Infection and Immunity|October 27, 2004
Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopesElizabeth H Nardin, Giane A Oliveira, J Mauricio Calvo-Calle, et al.Vaccine|March 22, 2002
Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoitesJames G Kublin, Mark H Lowitt, Robert G Hamilton, et al.Vaccine|November 27, 2002
Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoitesRobert Edelman, Steven S Wasserman, James G Kublin, et al.Infection and Immunity|May 24, 2005
Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trialGiane A Oliveira, Kristiane Wetzel, J Mauricio Calvo-Calle, et al.Pageof 1